Loading clinical trials...

Case Managers for CVD Risk Reduction in HIV Clinic | Clinical Trials | Clareo Health

COMPLETEDNA

Case Managers for CVD Risk Reduction in HIV Clinic

A Clinic-Based Case Manager Administered Telephone Intervention to Reduce Cardiovascular Disease Risk in Persons Living With HIV

NCT03839394•Duke University

View on ClinicalTrials.gov

Summary

The purpose of the study is to assess the efficacy of a case manager/social worker administered, telephone-based educational curriculum in improving cardiovascular disease related outcomes among HIV-infected clinic patients.

Detailed Description

Fifty high Cardiovascular Disease Risk (CVD) risk clinic patients will be randomized 1:1 to receive either a series of educational pamphlets on CVD risk reduction plus a telephone-based CVD risk reduction curriculum delivered over 24 weeks \[intervention arm\], or the educational pamphlets alone \[control arm\]. Anthropomorphic data, blood pressure and lipid profiles will be obtained from patients to assess the efficacy of the intervention in reducing blood pressure and serum low-density lipoprotein levels (LDL).

Eligibility

Age

40 - 75 years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•In care at the Duke Infectious Diseases Clinic for HIV and for at least 24 months
•On antiretroviral therapy
•2013 American Heart Association 10-year ASCVD risk score ≥ 15%, with a diagnosis of either hypertension or hyperlipidemia
•English literate (able to speak and read at a 6th grade level)
•Subjects must have the capacity to give legally effective consent.

Exclusion Criteria

•Patients with prior diagnosis of acute coronary syndrome, stroke, peripheral vascular disease, and end stage renal disease

Locations (1)

Duke University Medical Center

Durham, North Carolina, United States

Key Dates

Start Date

October 12, 2020

Primary Completion Date

September 14, 2023

Completion Date

September 14, 2023

Last Updated

September 24, 2024

Enrollment

ACTUAL participants

Conditions

Cardiovascular DiseaseHIV

Interventions

Telephone

BEHAVIORAL

Educational pamphlets

OTHER

Dietary Omega-7 Palmitoleic Acid-Rich Oil on Lipoprotein Metabolism and Satiety in Adults

NCT03372733

Cardiovascular Disease

View study

RECRUITINGPHASE2

Therapy Adapted for High Risk and Low Risk HIV-Associated Anal Cancer

NCT04929028

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: September 24, 2024Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

Case Managers for CVD Risk Reduction in HIV Clinic

Inclusion Criteria

Exclusion Criteria

Dietary Omega-7 Palmitoleic Acid-Rich Oil on Lipoprotein Metabolism and Satiety in Adults

Therapy Adapted for High Risk and Low Risk HIV-Associated Anal Cancer

Thinking and Memory Problems in People With HIV

A Study of MK-8527 to Prevent Human Immunodeficiency Virus Type 1 (HIV-1) (MK-8527-010)

A Study of Orforglipron (LY3502970) on Cardiovascular Outcomes in Adults With Atherosclerotic Cardiovascular Disease and/or Chronic Kidney Disease (ATTAIN-Outcomes)

Long-acting Cabotegravir Injectable Pre-exposure Prophylaxis for People Who Inject Drugs